Cardiopulmonary bypass in patients with pre-existing coagulopathy

Journal of Extra-Corporeal Technology

Volumn 37, Issue 1, 2005, Pages 15-22

  DeBois, William ^a   Liu, Junli ^a   Lee, Leonard ^a   Girardi, Leonard ^a   Ko, Wilson ^a   Tortolani, Anthony ^a   Krieger, Karl ^a   Isom, O Wayne ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Cardiopulmonary bypass; Coagulopathy; Heparinization; Thrombosis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 12; FIBRINOGEN RECEPTOR; HEPARIN; PROTEIN S; THROMBOCYTE SLOWING FACTOR;

ANTITHROMBIN III DEFICIENCY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 12 DEFICIENCY; CANCER; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HEMOPHILIA; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PROTEIN S DEFICIENCY; RISK FACTOR; SICKLE CELL ANEMIA;

EID: 14644399782     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (82)

1. Gerhardt MA, Greenberg CS, Slaughter TF, Smith MS. Factor XII deficiency and cardiopulmonary bypass. Anesthesiology. 1997;87:990-2.
2. Kelsey PR, Bottomley J, Grotte GJ, Maciver JE. Congenital factor XII deficiency: Successful open heart surgery and anticoagulation. Clin Lab Haematol. 1985;7:379-81.
3. Salmenpera M, Rasi V, Mattila S. Cardiopulmonary bypass in a patient with factor XII deficiency. Anesthesiology. 1991;75:539-41.
4. Moorman RM, Reynolds DS, Comunale ME. Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency. J Cardiothorac Vasc Anesth. 1993;7:452-4.
5. Wood MK. Congenital factor XII deficiency and cardiopulmonary bypass. Ann Thorac Surg. 1994;58:1565.
6. Wallock M, Arentzen C. Factor XII deficiency and cardiopulmonary bypass. Perfusion. 1995;10:13-6.
7. Burman JF, Chung HI, Lane DA, Philippou H, Adami A, Lincoln JCR. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet. 1994;344:1192-3.
8. Nahas C, Jones JW, Beall AC, Lafuente J, Irani M. Myocardial revascularization in a hemophiliac. Cardiovasc Surg. 1996;4:557-8.
9. Mackinlay N, Taper J, Renisson F, Rickard K. Cardiac surgery and catheterization in patients with haemophilia. Haemophilia. 2000;6:84-8.
10. Bretler DB, Levine PH. Factor concentrations for treatment of hemophilia: Which one to choose. Blood. 1989;73:2067-73.
11. Horrow JC. Desmopressin and antifibrinolytics. Int Anesthesiol Clin. 1990;28:230-6.
12. Koner O, Cetin G, Karaoglu K, Seren S, Bakay C. Fresh whole blood and immunoglobulin permit coronary artery bypass graft surgery in patients with idiopathic thrombocytopenic purpura. J Cardiothorac Vase Anesth. 2001;15:483-4.
13. Christiansen S, Schmid C, Redmann K, et al. Preoperative immunoglobulin treatment in patients with Werlhof's disease undergoing cardiac operation. Ann Thorac Surg. 2000;69:61-4.
14. Fujisawa K, Tani P, Piro L, McMillan R. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. Blood. 1993;81:2872-3.
15. Nakamura K, Onitsuka T, Yano M, Nagahama H, Nakamura E, Matsuzaki Y. Nafamostat mesilate treatment during open heart operation in immune thrombocytopenic purpura. Ann Thorac Surg. 2000;70:2161-3.
16. Christiansen S, Rotker J, Roeder N, et al. Are patients with Werlhof's disease at increased risk for bleeding complications with undergoing cardiac surgery? Eur J Cardiothorac Surg. 2000;18:353-6.
17. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg. 1984;37:359-64.
18. Shulman G, McQuitty C, Vertrees RA, Conti VR. Acute normovolemic red cell exchange for cardiopulmonary bypass in sickle cell disease. Ann Thorac Surg. 1998;65:1444-6.
19. Black HA, Dearing JP. Exchange transfusion prior to cardiopulmonary bypass in sickle cell anemia. J ExtraCorp Technol. 1980;12:82-5.
20. Balusundaram S, Duran CG, Al-Halees Z, Kassay M. Cardiopulmonary bypass in sickle cell anemia. Report of five cases. J Cardiovasc Surg. 1991;32:271-4.
21. Chun PKC, Flannery EP, Bowen TE. Open-heart surgery in patients with hematologic disorders. Am Heart J. 1983;105:835-42.
22. Frimpong-Boateng K, Amoah AGB, Barwasser HM, Kallen C. Cardiopulmonary bypass in sickle cell anaemia without exchange transfusion. Eur J Cardiothorac Surg. 1998;14:527-9.
23. Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981;68:1221-8.
24. Van Hinsbergh VWM, Bertina RM, van Wijngaarden A. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood. 1985;65:444-51.
25. Grocott HP, Clements F, Landolfo K. Coronoary artery bypass graft surgery in a patient with hereditary protein S deficiency. J Cardiothorac Vasc Anesth. 1996;10:915-7.
26. Engesser L. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med. 1987;106:677-82.
27. Villacorta J, Guidon C, Kerbaul F, Mesana T, Gouin F. An intraoperative coronary artery bypass graft thrombosis in a patient with protein S deficiency. J Cardiothorac Vasc Anesth. 2001;15:805-7.
28. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998;97:211-8.
29. Alvarez JM. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg. 1998;115:472-3.
30. Gammie JS, Zenati M, Kormos RL, Hattler BG, Pellegrini RV. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg. 1998;65:465-9.
31. Lefkovits J, Ivanhoe RJ, Califf RM. Effects of platelet glycoprotein receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous translunimal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol. 1996;77:1045-51.
32. Silvestry SC, Smith PK. Current status of cardiac surgery in the abciximab-treated patient. Ann Thorac Surg. 2000;70:S12-9.
33. Dyke C, Gammie JS. Surgical implications of platelet glycoprotein IIb/IIIa inhibition. J Thorac Cardiovasc Surg. 1998;116:1083-4.
34. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-96.
35. Gammies JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg. 1998;65:465-9.
36. Kereiakes DJ. Prophylactic platelet transfusion in abciximab treated patients requiring coronary bypass surgery (letter). Am J Cardiol. 1998;81:373.
37. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg. 1998;66:2145-52.
38. Poullis M, Manning R, Haskard D, Taylor K. Reopro removal during cardiopulmonary bypass using a hemoconcentrator. J Thorac Cardiovasc Surg. 1999;117:1032-4.
39. Van Norman GA, Gernsheimer T, Chandler WL, Cochran RP, Spiess BD. Indicator of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency. J Cardiothorac Vasc Anesth. 1997;11:760-3.
40. Fourrier F, Chopin C, Huart J. Double-blind, placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882-8.
41. Lidon RM, Theroux P, Robitaille D, Runge I, Caron C, Goudemand J. Antithrombin III plasma activity during and after prolonged use of heparin in unstable angina. Throm Res. 1993;72:23-32.
42. Uppington J. Anesthetic management of patients with coagulation disorders. Int Anesthesiol Clin. 1985;23:125-40.
43. Piszkiewicz D, Apfelzweig R, Bourret L, et al. Inactivation of HIV in antithrombin III concentrate by pasteurization (letter). Transfusion. 1998;28:198-9.
44. Menache D, O'Malley JP, Schorr JB, Wagner B, Willians C. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood. 1990;75:33-9.
45. Rossi M, Martinelli L, Storti S, et al. The role of antithrombin III in the perioperative management of the patient with unstable angina. Ann Thorac Surg. 1999;68:2231-6.
46. Baglin TP. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: Diagnosis and treatment. J Clin Pathol. 2001;54:272-4.
47. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001;113:886-90.
48. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost. 1995;73:21-8.
49. Follis F, Schmidt CA. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg. 2000;70:2173-81.
50. Mollison PL, Engelfriet CP, Contreras M Blood Transfusion in Clinical Medicine. 9th ed. Oxford, England: Blackwell Scientific; 1993.
51. Potzsch B, Klovekorn WP. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombobytopenia. N Engl J Med. 2001;343:515.
52. Frederiksen JW. Cardiopulmonary bypass in human: bypass unfractioned heparin. Ann Thorac Surg. 2000;70:1434-43.
53. Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M. Cardiopulmonary bypass with a low-molecular weight heparin fraction. Lancet. 1983;2:1374.
54. Prifti E, Bonacchi M, Leacche M, Miraldi F. Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure. Eur J Cardiothorac Surg. 2000;17:760-2.
55. Arnoletti JP, Whitman GJR. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann Thorac Surg. 1999;68:576-8.
56. Magnani HN, Beijering RJR, et al. Organ anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus; 1997; 487-500.
57. Zulys VJ, Teasdale SJ, Michel ER, et al. Ancrod as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989;71:870-7.
58. Potzsch B, Iversen S, et al. Recombinant hirudin as an anticoagulant in open-heart surgery: A case report. Ann Hematol. 1994;68:A53.
59. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Throm Haemost. 1998;80:292-7.
60. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment - an evaluation of native blood and plasma assays. Throm Haemost. 1994;72:685-92.
61. Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time. Thromb Haemost. 1997;77:920-5.
62. Konkle BA, Bauer TL, Arepally G, et al. Heparin-induced thrombocytopenia:bovine versus porcine Heparin in cardiopulmonary bypass surgery. Ann Thorac Surg. 2001;71:1920-4.
63. Gordon G, Rastegar H, Schumann R, Deiss-Shrem J, Denman W. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth. 2003;17:632-5.
64. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2003;75:264-5.
65. Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA Jr. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg. 2002;74:2177-9.
66. Merry AF. Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery. Semin Thromb Hemost. 2004;36:337-46.
67. Kakkar AK, Williamson RCN. Prevention of VET in cancer patients. Semin Thromb Hemost. 1999;25:239-43.
68. Clagett GP, Reisch JS. Prevention of VET in general surgical patients: results of a meta-analysis. Ann Surg. 1998;208:227-40.
69. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis and treatment. Am J Hemat. 2003;72:43-52.
70. Roger LR. Cerebrovascular complications in cancer patients. Neurologic Clinics. 2003;21:167-92.
71. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev. 1992;11:249-66.
72. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: A cysteine proteinase form malignant tissue. Biochemistry. 1985;24:5558-67.
73. Dashmahapatra KS, Cheung NK, Spillert C, Lazaro E. An assessment of monocyte procoagulant activity in patients with solid tumor. J Surg Res. 1987;43:158-63.
74. Falanga A, Rickles FR. Pathophysiology of thrombophilic state in the cancer patient. Semin Thromb Haemost. 1992;25:173-82.
75. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor Vila and tissue factor. Lancet. 1995;346:1004-5.
76. Nijziel MR, Oerle RV, Christella M, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol. 2003; 120:117-22.
77. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke. 1994;25:1215-8.
78. Hedderich GS, O'Connor RJ, Reid EC, Mulder DS. Caval tumor thrombus complicating renal cell carcinoma: A surgical challenge. Surgery. 1988;102:614-9.
79. Harvey RL, Mychaskiw G, Sachdev V, Heath BJ. Isolated cardiac metastasis of cervical carcinoma presenting as disseminated intravascular coagulopathy. J Reprod Med. 2000;45:603-6.
80. Milligan NS, Edwards JC, Monro JL, Atwell JD. Excision of giant haemangioma in the newborn using hypothermia and cardiopulmonary bypass. Anaesthesia. 1985;40:875-8.
81. Stewart JR, Carey JA, McDougal WS, Merrill WH, Koch MO, Bender HW. Cavoatrial tumor thrombectomy using cardiopulmonary bypass without circulatory arrest. Ann Thorac Surg. 1991;51:717-22.
82. Chun PKC, Flannery EP, Bowen TE. Open-heart surgery in patients with hematologic disorders. Am Heart J. 1983;105:835-42.